Literature DB >> 3036388

In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines.

H Roed, L L Vindeløv, M Spang-Thomsen, I J Christensen, H H Hansen.   

Abstract

The cytotoxic activity of a new nitrosourea, TCNU, was compared with that of BCNU in five human small cell lung cancer cell lines in vitro. TCNU was found to be equivalent or inferior to BCNU when compared on a microgram to microgram basis. If the potential of in vitro phase II trials for selection of new drugs can be validated, it can be concluded that TCNU is not superior to other nitrosoureas for the treatment of SCCL.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3036388     DOI： 10.1007/BF00261480

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  10 in total

1.  Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.

Authors:  V T De Vita; P P Carbone; A H Owens; G L Gold; M J Krant; J Edmonson
Journal:  Cancer Res       Date:  1965-12       Impact factor: 12.701

2.  Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines.

Authors:  H Roed; I B Christensen; L L Vindeløv; M Spang-Thomsen; H H Hansen
Journal:  Eur J Cancer Clin Oncol       Date:  1987-02

3.  A critical appraisal of the "human tumor stem-cell assay".

Authors:  P Selby; R N Buick; I Tannock
Journal:  N Engl J Med       Date:  1983-01-20       Impact factor: 91.245

4.  Chemosensitivity of human small cell carcinoma of the lung detected by flow cytometric DNA analysis of drug-induced cell cycle perturbations in vitro.

Authors:  S A Engelholm; M Spang-Thomsen; L L Vindeløv; N A Brünner
Journal:  Cytometry       Date:  1986-05

5.  The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.

Authors:  H Roed; L L Vindelov; I J Christensen; M Spang-Thomsen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Nitrosoureas: 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962; BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC-79037; CCNU)--clinical brochure.

Authors:  S K Carter; J W Newman
Journal:  Cancer Chemother Rep 3       Date:  1968-12

7.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis.

Authors:  L L Vindeløv; I J Christensen; N I Nissen
Journal:  Cytometry       Date:  1983-03

8.  Pharmacokinetics of BCNU in man: a preliminary study of 20 patients.

Authors:  V A Levin; W Hoffman; R J Weinkam
Journal:  Cancer Treat Rep       Date:  1978-09

9.  Long-term storage of samples for flow cytometric DNA analysis.

Authors:  L L Vindeløv; I J Christensen; N Keiding; M Spang-Thomsen; N I Nissen
Journal:  Cytometry       Date:  1983-03

10.  A short-term in vitro test for tumour sensitivity to adriamycin based on flow cytometric DNA analysis.

Authors:  S A Engelholm; M Spang-Thomsen; L L Vindeløv
Journal:  Br J Cancer       Date:  1983-04       Impact factor: 7.640
  10 in total
  6 in total

1.  Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines.

Authors:  P B Jensen; H Roed; L Vindeløv; I J Christensen; H H Hansen
Journal:  Invest New Drugs       Date:  1989-11       Impact factor: 3.850

2.  Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU).

Authors:  B Hartley-Asp; P I Christensson; K Gunnarsson; P O Gunnarsson; G Jensen; J Polacek; A Stamvik
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

3.  Pharmacokinetics of tauromustine in cancer patients. Phase I studies.

Authors:  P O Gunnarsson; J Vibe-Petersen; J S Macpherson; P S Warrington; J Polacek; M Ellman; H H Hansen; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.

Authors:  J L Fischel; P Formento; M C Etienne; J Gioanni; M Frenay; P Deloffre; J P Bizzari; G Milano
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity.

Authors:  P B Jensen; H Roed; M Sehested; E J Demant; L Vindeløv; I J Christensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Activity of a new nitrosourea (TCNU) in human lung cancer xenografts.

Authors:  R J Fergusson; L E Anderson; J S Macpherson; P Robins; J F Smyth
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.